Seminars in Oncology
Volume 32, Issue 3 , Pages 259-268 , June 2005

Novel Strategies for the Early Detection and Prevention of Lung Cancer

  • Noel R. Wardwell Jr
    • ,
  • Pierre P. Massion

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Pierre P. Massion, MD, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Nashville, TN 37232-6838

References 

  1. Jemal A , Ward E , Murray T , et al.   Cancer statistics, 2005 . CA Cancer J Clin . 2005;55:10–30
  2. Weir HK , Thun MJ , Hankey BF , et al.   Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control . J Natl Cancer Inst . 2003;95:1276–1299
  3. Edwards BK , Howe HL , Ries LA , et al.   Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden . Cancer . 2002;94:2766–2792
  4. Mountain CF . Revisions in the International System for Staging Lung Cancer . Chest . 1997;111:1710–1717
  5. National Cancer Institute: Surveillance Epidemiology and End Results Program (Online). http://seer.cancer.gov, 2002
  6. Humphrey LL , Teutsch S , Johnson M . Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography (An update for the U.S. Preventive Services Task Force) . Ann Intern Med . 2004;140:740–753
  7. Flehinger BJ , Kimmel M , Melamed MR . The effect of surgical treatment on survival from early lung cancer. Implications for screening . Chest . 1992;101:1013–1018
  8. Chan CK , Wells CK , McFarlane MJ , et al.   More lung cancer but better survival. Implications of secular trends in “necropsy surprise” rates . Chest . 1989;96:291–296
  9. Sone S , Takashima S , Li F , et al.   Mass screening for lung cancer with mobile spiral computed tomography scanner . Lancet . 1998;351:1242–1245
  10. National Cancer Institute: National Lung Screening Trial. http://www.cancer.gov/nlst, 2003
  11. Deschamps C , Pairolero PC , Trastek VF , et al.   Multiple primary lung cancers. Results of surgical treatment . J Thorac Cardiovasc Surg . 1990;99:769–777
  12. Pairolero PC , Williams DE , Bergstralh EJ , et al.   Postsurgical stage I bronchogenic carcinoma (Morbid implications of recurrent disease) . Ann Thorac Surg . 1984;38:331–338
  13. Ribet M , Dambron P . Multiple primary lung cancers . Eur J Cardiothorac Surg . 1995;9:231–236
  14. Van Meerbeeck J , Weyler J , Thibaut A , et al.   Second primary lung cancer in Flanders (Frequency, clinical presentation, treatment and prognosis) . Lung Cancer . 1996;15:281–295
  15. Peto R , Darby S , Deo H , et al.   Smoking, smoking cessation, and lung cancer in the UK since 1950 (Combination of national statistics with two case-control studies) . BMJ . 2000;321:323–329
  16. Tockman MS , Gupta PK , Myers JD , et al.   Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells (A new approach to early lung cancer detection) . J Clin Oncol . 1988;6:1685–1693
  17. Prindiville SA , Byers T , Hirsch FR , et al.   Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction . Cancer Epidemiol Biomarkers Prev . 2003;12:987–993
  18. Wu X , Zhao H , Suk R , et al.   Genetic susceptibility to tobacco-related cancer . Oncogene . 2004;23:6500–6523
  19. Amos CI , Xu W , Spitz MR . Is there a genetic basis for lung cancer susceptibility? . Recent Results Cancer Res . 1999;151:3–12
  20. Carmelli D , Swan GE , Robinette D , et al.   Genetic influence on smoking—A study of male twins . N Engl J Med . 1992;327:829–833
  21. Arinami T , Ishiguro H , Onaivi ES . Polymorphisms in genes involved in neurotransmission in relation to smoking . Eur J Pharmacol . 2000;410:215–226
  22. Bailey-Wilson JE , Amos CI , Pinney SM , et al.   A major lung cancer susceptibility locus maps to chromosome 6q2325 . Am J Hum Genet . 2004;75:460–474
  23. Brett GZ . The value of lung cancer detection by six-monthly chest radiographs . Thorax . 1968;23:414–420
  24. Brett GZ . Earlier diagnosis and survival in lung cancer . Br Med J . 1969;4:260–262
  25. Fontana RS , Sanderson DR , Taylor WF , et al.   Early lung cancer detection (Results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study) . Am Rev Respir Dis . 1984;130:561–565
  26. Kubik A , Polak J . Lung cancer detection. Results of a randomized prospective study in Czechoslovakia . Cancer . 1986;57:2427–2437
  27. Berlin NI . Overview of the NCI Cooperative Early Lung Cancer Detection Program . Cancer . 2000;89:2349–2351
  28. Truong MT , Munden RF . Lung cancer screening . Curr Oncol Rep . 2003;5:309–312
  29. Bach PB , Kelley MJ , Tate RC . Screening for lung cancer (A review of the current literature) . Chest . 2003;123(suppl 1):72S–82S
  30. Mulshine JL , Cuttitta F , Tockman MS , et al.   Lung cancer evolution to preinvasive management . Clin Chest Med . 2002;23:37–48
  31. Swensen SJ , Jett JR , Hartman TE , et al.   Lung cancer screening with CT (Mayo Clinic experience) . Radiology . 2003;226:756–761
  32. Henschke CI , Naidich DP , Yankelevitz DF , et al.   Early lung cancer action project (Initial findings on repeat screenings) . Cancer . 2001;92:153–159
  33. Mori M , Rao SK , Popper HH , et al.   Atypical adenomatous hyperplasia of the lung (A probable forerunner in the development of adenocarcinoma of the lung) . Mod Pathol . 2001;14:72–84
  34. Kerr KM . Pulmonary preinvasive neoplasia . J Clin Pathol . 2001;54:257–271
  35. Nagao M , Murase K , Yasuhara Y , et al.   Measurement of localized ground-glass attenuation on thin-section computed tomography images (Correlation with the progression of bronchioloalveolar carcinoma of the lung) . Invest Radiol . 2002;37:692–697
  36. Nakata M , Saeki H , Takata I , et al.   Focal ground-glass opacity detected by low- dose helical CT . Chest . 2002;121:1464–1467
  37. Swensen SJ , Jett JR , Sloan JA , et al.   Screening for lung cancer with low-dose spiral computed tomography . Am J Respir Crit Care Med . 2002;165:508–513
  38. Sobue T , Moriyama N , Kaneko M , et al.   Screening for lung cancer with low-dose helical computed tomography (anti-lung cancer association project) . J Clin Oncol . 2002;20:911–920
  39. Sone S , Li F , Yang ZG , et al.   Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner . Br J Cancer . 2001;84:25–32
  40. Lowe VJ , Fletcher JW , Gobar L , et al.   Prospective investigation of positron emission tomography in lung nodules . J Clin Oncol . 1998;16:1075–1084
  41. Herder GJ , Verboom P , Smit EF , et al.   Practice, efficacy and cost of staging suspected non-small cell lung cancer (A retrospective study in two Dutch hospitals) . Thorax . 2002;57:11–14
  42. Canadian Lung Oncology Group . Investigation for mediastinal disease in patients with apparently operable lung cancer . Ann Thorac Surg . 1995;60:1382–1389
  43. Lardinois D , Weder W , Hany TF , et al.   Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography . N Engl J Med . 2003;348:2500–2507
  44. Pastorino U , Bellomi M , Landoni C , et al.   Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers (2-year results) . Lancet . 2003;362:593–597
  45. Lam S , Kennedy T , Unger M , et al.   Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy . Chest . 1998;113:696–702
  46. Hirsch FR , Prindiville SA , Miller YE , et al.   Fluorescence versus white- light bronchoscopy for detection of preneoplastic lesions (a randomized study) . J Natl Cancer Inst . 2001;93:1385–1391
  47. Kusunoki Y , Imamura F , Uda H , et al.   Early detection of lung cancer with laser-induced fluorescence endoscopy and spectrofluorometry . Chest . 2000;118:1776–1782
  48. Sato M , Sakurada A , Sagawa M , et al.   Diagnostic results before and after introduction of autofluorescence bronchoscopy in patients suspected of having lung cancer detected by sputum cytology in lung cancer mass screening . Lung Cancer . 2001;32:247–253
  49. Carroll FE . Tunable monochromatic x rays (A new paradigm in medicine) . AJR Am J Roentgenol . 2002;179:583–590
  50. Schellenberger EA , Bogdanov A , Hogemann D , et al.   Annexin V-CLIO (A nanoparticle for detecting apoptosis by MRI) . Mol Imaging . 2002;1:102–107
  51. Schellenberger EA , Bogdanov A , Petrovsky A , et al.   Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy . Neoplasia . 2003;5:187–192
  52. Blasberg RG , Gelovani J . Molecular-genetic imaging (A nuclear medicine-based perspective) . Mol Imaging . 2002;1:280–300
  53. Huang Z , McWilliams A , Lui H , et al.   Near-infrared Raman spectroscopy for optical diagnosis of lung cancer . Int J Cancer . 2003;107:1047–1052
  54. Welzel J . Optical coherence tomography in dermatology (A review) . Skin Res Technol . 2001;7:1–9
  55. Kanamori A , Nakamura M , Escano MF , et al.   Evaluation of the glaucomatous damage on retinal nerve fiber layer thickness measured by optical coherence tomography . Am J Ophthalmol . 2003;135:513–520
  56. Sung JJ . Changing role of endoscopy in the new millennium. Bushell Lecture, Asia-Pacific Digestive Week 2001 . J Gastroenterol Hepatol . 2002;17:369–373
  57. Yanagisawa K , Shyr Y , Xu BJ , et al.   Proteomic patterns of tumour subsets in non-small-cell lung cancer . Lancet . 2003;362:433–439
  58. Satoh Y , Ishikawa Y , Nakagawa K , et al.   A follow-up study of progression from dysplasia to squamous cell carcinoma with immunohistochemical examination of p53 protein overexpression in the bronchi of ex-chromate workers . Br J Cancer . 1997;75:678–683
  59. Braithwaite KL , Rabbitts PH . Multi-step evolution of lung cancer . Semin Cancer Biol . 1999;9:255–265
  60. Ishikawa Y , Nakagawa K , Satoh Y , et al.   Characteristics of chromate workers’ cancers, chromium lung deposition and precancerous bronchial lesions (An autopsy study) . Br J Cancer . 1994;70:160–166
  61. Auerbach O , Stout AP , Hammond EC , et al.   Changes in bronchial epithelum in reation to cigraette smoking and in relation to lung cancer . N Engl J Med . 1961;265:253–267
  62. Emmert-Buck MR , Bonner RF , Smith PD , et al.   Laser capture microdissection . Science . 1996;274:998–1001
  63. Hanahan D , Weinberg RA . The hallmarks of cancer . Cell . 2000;100:57–70
  64. Belinsky SA , Nikula KJ , Baylin SB , et al.   Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer . Proc Natl Acad Sci U S A . 1996;93:4045–4050
  65. Brambilla E , Gazzeri S , Lantuejoul S , et al.   p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer . Clin Cancer Res . 1998;4:1609–1618
  66. Thiberville L , Payne P , Vielkinds J , et al.   Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus . Cancer Res . 1995;55:5133–5139
  67. Lavieille JP , Gazzeri S , Riva C , et al.   p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck . Anticancer Res . 1998;18:4741–4749
  68. Jeanmart M , Lantuejoul S , Fievet F , et al.   Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer . Clin Cancer Res . 2003;9:2195–2203
  69. Massion PP , Taflan PM , Jamshedur Rahman SM , et al.   Significance of p63 amplification and overexpression in lung cancer development and prognosis . Cancer Res . 2003;63:7113–7121
  70. Slebos RJ , Baas IO , Clement MJ , et al.   p53 alterations in atypical alveolar hyperplasia of the human lung . Hum Pathol . 1998;29:801–808
  71. Aoyagi Y , Yokose T , Minami Y , et al.   Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma . Cancer Res . 2001;61:7950–7954
  72. Wistuba II , Behrens C , Virmani AK , et al.   High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints . Cancer Res . 2000;60:1949–1960
  73. Wistuba II , Behrens C , Milchgrub S , et al.   Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma . Oncogene . 1999;18:643–650
  74. Kishimoto Y , Sugio K , Hung JY , et al.   Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers . J Natl Cancer Inst . 1995;87:1224–1229
  75. Massion PP , Kuo WL , Stokoe D , et al.   Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization (Implications of the phosphatidylinositol 3-kinase pathway) . Cancer Res . 2002;62:3636–3640
  76. Massion PP , Taflan PM , Shyr Y , et al.   Early Involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression . Am J Respir Crit Care Med . 2004;170:1088–1094
  77. Liloglou T , Maloney P , Xinarianos G , et al.   Cancer-specific genomic instability in bronchial lavage (A molecular tool for lung cancer detection) . Cancer Res . 2001;61:1624–1628
  78. Cuda G , Gallelli A , Nistico A , et al.   Detection of microsatellite instability and loss of heterozygosity in serum DNA of small and non-small cell lung cancer patients (A tool for early diagnosis?) . Lung Cancer . 2000;30:211–214
  79. Esteller M , Sanchez-Cespedes M , Rosell R , et al.   Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients . Cancer Res . 1999;59:67–70
  80. Chen XQ , Stroun M , Magnenat JL , et al.   Microsatellite alterations in plasma DNA of small cell lung cancer patients . Nat Med . 1996;2:1033–1035
  81. Sozzi G , Musso K , Ratcliffe C , et al.   Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients (A prospect for early diagnosis) . Clin Cancer Res . 1999;5:2689–2692
  82. Sozzi G , Conte D , Leon M , et al.   Quantification of free circulating DNA as a diagnostic marker in lung cancer . J Clin Oncol . 2003;21:3902–3908
  83. Petty RD , Nicolson MC , Kerr KM , et al.   Gene expression profiling in non-small cell lung cancer (From molecular mechanisms to clinical application) . Clin Cancer Res . 2004;10:3237–3248
  84. Beer DG , Kardia SL , Huang CC , et al.   Gene-expression profiles predict survival of patients with lung adenocarcinoma . Nat Med . 2002;8:816–824
  85. Chen JJ , Peck K , Hong TM , et al.   Global analysis of gene expression in invasion by a lung cancer model . Cancer Res . 2001;61:5223–5230
  86. Yamagata N , Shyr Y , Yanagisawa K , et al.   A training-testing approach to the molecular classification of resected non-small cell lung cancer . Clin Cancer Res . 2003;9:4695–4704
  87. Yanagawa N , Tamura G , Oizumi H , et al.   Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers . Cancer Sci . 2003;94:589–592
  88. Ahrendt SA , Chow JT , Xu LH , et al.   Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer . J Natl Cancer Inst . 1999;91:332–339
  89. Usadel H , Brabender J , Danenberg KD , et al.   Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer . Cancer Res . 2002;62:371–375
  90. Brabender J , Usadel H , Metzger R , et al.   Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer (Associations with clinical outcome) . Clin Cancer Res . 2003;9:223–227
  91. Fleischhacker M , Beinert T , Ermitsch M , et al.   Detection of amplifiable messenger RNA in the serum of patients with lung cancer . Ann N Y Acad Sci . 2001;945:179–188
  92. Fielding P , Turnbull L , Prime W , et al.   Heterogeneous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens (A clinical marker of early lung cancer detection) . Clin Cancer Res . 1999;5:4048–4052
  93. Dubinett SM , Sharma S , Huang M , et al.   Cyclooxygenase-2 in lung cancer . Prog Exp Tumor Res . 2003;37:138–162
  94. Hosomi Y , Yokose T , Hirose Y , et al.   Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung . Lung Cancer . 2000;30:73–81
  95. Hasturk S , Kemp B , Kalapurakal SK , et al.   Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma . Cancer . 2002;94:1023–1031
  96. Hirsch FR , Varella-Garcia M , Bunn PA , et al.   Epidermal growth factor receptor in non-small-cell lung carcinomas (Correlation between gene copy number and protein expression and impact on prognosis) . J Clin Oncol . 2003;21:3798–3807
  97. Adjei AA . An overview of farnesyltransferase inhibitors and their role in lung cancer therapy . Lung Cancer . 2003;41(suppl 1):S55–S62
  98. Chaurand P , Stoeckli M , Caprioli RM . Direct profiling of proteins in biological tissue sections by MALDI mass spectrometry . Anal Chem . 1999;71:5263–5270
  99. Chen G , Gharib TG , Wang H , et al.   Protein profiles associated with survival in lung adenocarcinoma . Proc Natl Acad Sci U S A . 2003;100:13537–13542
  100. Sidransky D , Irizarry R , Califano JA , et al.   Serum protein MALDI profiling to distinguish upper aerodigestive tract cancer patients from control subjects . J Natl Cancer Inst . 2003;95:1711–1717
  101. Howard BA , Wang MZ , Campa MJ , et al.   Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis . Proteomics . 2003;3:1720–1724
  102. Sullivan Pepe M , Etzioni R , Feng Z , et al.   Phases of biomarker development for early detection of cancer . J Natl Cancer Inst . 2001;93:1054–1061
  103. Kononen J , Bubendorf L , Kallioniemi A , et al.   Tissue microarrays for high-throughput molecular profiling of tumor specimens . Nat Med . 1998;4:844–847
  104. Hong WK , Lippman SM , Itri LM , et al.   Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck . N Engl J Med . 1990;323:795–801
  105. Pastorino U , Infante M , Maioli M , et al.   Adjuvant treatment of stage I lung cancer with high-dose vitamin A . J Clin Oncol . 1993;11:1216–1222
  106. Omenn GS , Goodman G , Thornquist M . The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations (Smokers and asbestos-exposed workers) . Cancer Res . 1994;54(suppl 7):2038s–2043s
  107. Furukawa F , Nishikawa A , Lee IS , et al.   A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters . Int J Cancer . 2003;104:269–273
  108. Gridelli C , Maione P , Airoma G , et al.   Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer . Curr Med Chem . 2002;9:1851–1858
  109. Harris RE , Beebe-Donk J , Schuller HM . Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers . Oncol Rep . 2002;9:693–695
  110. Arteaga CL , Johnson DH . Tyrosine kinase inhibitors-ZD1839 (Iressa) . Curr Opin Oncol . 2001;13:491–498
  111. Subongkot S , Frame D , Leslie W , et al.   Selective cyclooxygenase-2 inhibition (A target in cancer prevention and treatment) . Pharmacotherapy . 2003;23:9–28
  112. Johnson DH . Gefitinib (Iressa) trials in non-small cell lung cancer . Lung Cancer . 2003;41(suppl 1):S23–S28
  113. Kelloff GJ , Lubet RA , Fay JR , et al.   Farnesyl protein transferase inhibitors as potential cancer chemopreventives . Cancer Epidemiol Biomarkers Prev . 1997;6:267–282
  114. Scharovsky OG , Rozados VR , Gervasoni SI , Matar P . Inhibition of ras oncogene (A novel approach to antineoplastic therapy) . J Biomed Sci . 2000;7:292–298
  115. Langer CJ . Role of targeted therapy in non-small cell lung cancer (Hype or hope?) . Expert Rev Anticancer Ther . 2003;3:443–455
  116. Caponigro F , Casale M , Bryce J . Farnesyl transferase inhibitors in clinical development . Expert Opin Investig Drugs . 2003;12:943–954
  117. Mulshine JL , Hirsch FR . Lung cancer chemoprevention (Moving from concept to a reality) . Lung Cancer . 2003;41(suppl 1):S163–S174
  118. Herbst RS , Maddox AM , Rothenberg ML , et al.   Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors (Results of a phase I trial) . J Clin Oncol . 2002;20:3815–3825
  119. Akhmedkhanov A , Toniolo P , Zeleniuch-Jacquotte A , et al.   Aspirin and lung cancer in women . Br J Cancer . 2002;87:49–53
  120. Weis M , Heeschen C , Glassford AJ , et al.   Statins have biphasic effects on angiogenesis . Circulation . 2002;105:739–745
  121. Costantini V , Fuschiotti P , Giampietri A , et al.   Effects of a stable prostacyclin analogue on platelet activity and on host immunocompetence in mice . Prostaglandins . 1990;39:581–599
  122. Keith RL , Miller YE , Hoshikawa Y , et al.   Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer . Cancer Res . 2002;62:734–740
  123. Henschke CI , McCauley DI , Yankelevitz DF , et al.   Early Lung Cancer Action Project (Overall design and findings from baseline screening) . Lancet . 1999;354:99–105

 Supported by the Department of Veterans Affairs, the Flight Attendant Medical Research Institute, the Damon Runyon Cancer Research Foundation, and the SPORE in Lung Cancer 5P50 CA 90949-02.

PII: S0093-7754(05)00079-5

doi: 10.1053/j.seminoncol.2005.02.009

Seminars in Oncology
Volume 32, Issue 3 , Pages 259-268 , June 2005

Article Tools

* Image Usage & Resolution